Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03054363 | Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 42 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00634634 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 9, 2023 |
| NCT02599363 | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03304210 | PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer(PIPAC-nabpac) | completed | Phase 1 | 20 | University Hospital, GhentOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01717261 | Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer(SPORT) | completed | Phase 1 | 10 | Maisonneuve-Rosemont HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03840200 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 5 | Oct 30, 2023 | clinicaltrials |
| NCT00944528 | Single Dose Partial Breast Radiotherapy(RSU) | completed | Phase 1 | 35 | Duke UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | completed | Phase 1 | 105 | Syros PharmaceuticalsINDUSTRY | 1 | Oct 27, 2023 | clinicaltrials |
| NCT06098599 | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer | completed | Phase 1 | 48 | Luye Pharma Group Ltd.INDUSTRY | 1 | Oct 24, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06074757 | Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study | completed | Phase 1 | 48 | Kashiv BioSciences, LLCINDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00082641 | Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04367090 | Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer | completed | Phase 1 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01376505 | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | completed | Phase 1 | 65 | Robert WesolowskiOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03953833 | B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer(B003-101) | completed | Phase 1 | 30 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion(MpeTK01) | completed | Phase 1 | 19 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 19 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02649686 | Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03941743 | Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer | completed | Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00003927 | Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT00093834 | Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer | completed | Phase 1 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01837602 | cMet CAR RNA T Cells Targeting Breast Cancer | completed | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05860582 | A Study of [14C]GB491 in Male Healthy Subjects | completed | Phase 1 | 6 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT02531425 | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC(TNBC) | completed | Phase 1 | 10 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03310541 | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04097756 | A Phase I Study of LX-039 Tablets | completed | Phase 1 | 44 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812326 | PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02027376 | Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients(EDALINE) | completed | Phase 1 | 12 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT01306942 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | completed | Phase 1 / Phase 2 | 37 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT04382352 | B002 in Patients With HER2-positive Breast Cancer(B002-101) | completed | Phase 1 | 23 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT04837677 | A Study of PRT1419 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Prelude TherapeuticsINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05298696 | Efficacy of Cilostazol in Prevention of Peripheral Neuropathy | completed | Phase 1 / Phase 2 | 71 | Mansoura UniversityOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 13, 2023source: clinicaltrials